General MedicationsORALGeneric

UNIVASC

MOEXIPRIL HYDROCHLORIDE

Standard Dose

7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: UNKNOWN Marketing status: Discontinued

Summary

Approval overview UNIVASC is listed in Drugs@FDA under application 020312 (NDA).

Review priority: UNKNOWN Marketing status: Discontinued Active ingredient MOEXIPRIL HYDROCHLORIDE Form and strength TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor UCB INC Submission history Latest submission status date: 2012-09-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview UNIVASC is listed in Drugs@FDA under application 020312 (NDA). Review priority: UNKNOWN Marketing status: Discontinued Active ingredient MOEXIPRIL HYDROCHLORIDE Form and strength TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor UCB INC Submission history Latest submission status date: 2012-09-14 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: UNKNOWN

Interaction Notes

No interaction notes stored yet.